GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Looks like ‘sell on news’ wins again.
Shame it’s not classed as Fintech....then a £50bn valuation would seem reasonable!
Let’s wait for the analysts’ reports.
Generally, the sp direction pre-announcement gives a good indication of whether good or bad news. So, so far, so good...?
But be prepared for the old ‘sell on news’ manoeuvre.
‘Among those in the pipeline is Synairgen’s SNG001, an inhalable beta interferon. This type of drug helps reduce inflammation and the body’s immune reaction.’
‘.....and the body’s immune reaction’ ?
Not sure i’m happy with that phrase, since, to quote the co.
‘SNG001 is an inhaled formulation of interferon-beta-1a (IFN-ß1a), a respiratory drug which has been found to inhibit viruses and boost antiviral responses in the lungs.’
One of the issues at the time must surely have been around Synairgen’s ability (or not) to supply meaningful quantities of the product.
Also, the early comments by RM suggesting a price for SNG001 similar to Remdesivir’s were imho a major mistake.
On a ‘busy’ day about 2% of SNG stock is traded. Which suggests that 98% stays where it is.
So any trend is created by an active (very small) minority.
In the absence of any TR1s, it could be the same 2% traded each day.
Does seem that AZN and Synairgen have burnt their bridges. Perhaps the AZN guy was involved in the earlier decision to terminate the trial of SNG001 in asthma viral exacerbations?
Anyway, it’s AZN + Oxford representing Britain versus the RoW....
Budesonide falls into the ‘cheap and cheerful’ criteria quoted by Horby for the RECOVERY trial, so, like dexamethasone, has a head start.
Can’t personally see how early intervention with a steroid(anti-inflammatory) can be of use when the patient’s immune response needs a boost, not suppression!
As explained here
https://theconversation.com/steroids-cut-covid-19-death-rates-but-not-for-everyone-heres-who-benefits-and-who-doesnt-145605
And probably why Professor Sir Stephen Holgate appeared to dismiss it.
...people haven’t seen these maps
https://www.racap.com/covid-19
Then have a look as they’re the most comprehensive on current Covid developments and reflect a lot of detailed work.
PS - they’re complex charts.
The RECOVERY trial results for tocilizumab in a hospital setting were described as ‘stunning’; ‘impressive’; ‘significant’; ‘very welcome’; ‘life-saving’ etc etc by those in charge, based on :
‘Treatment with tocilizumab significantly reduced deaths: 596 (29%) of the patients in the tocilizumab group died within 28 days compared with 694 (33%) patients in the usual care group (rate ratio 0·86; [95% confidence interval [CI] 0·77 to 0·96]; p=0·007), an absolute difference of 4%. This means that for every 25 patients treated with tocilizumab, one additional life would be saved. Tocilizumab also increased the probability of discharge alive within 28 days from 47% to 54% (rate ratio 1·23, [95% CI 1·12 to 1·34], p<0·0001). These benefits were seen in all patient subgroups, including those requiring oxygen via a simple face mask through to those requiring mechanical ventilators in an intensive care unit.
Among patients not on invasive mechanical ventilation when entered into the trial, tocilizumab significantly reduced the chance of progressing to invasive mechanical ventilation or death from 38% to 33% (risk ratio 0·85, [95% CI 0·78 to 0·93], p=0·0005). However, there was no evidence that tocilizumab had any effect on the chance of successful cessation of invasive mechanical ventilation.’
—————————
So, with the right PR, relatively small improvements can be hailed as major achievements.
jaffjoon,
Whitty’s comments on Tocilizumab are designed, imho, to show what an amazingly successful effort the RECOVERY trial has been and all those participating in it, funding it and sponsoring it should be congratulated.
This tone is confirmed by the Press Release announcing the ‘significant’ results so far:
https://www.recoverytrial.net/news/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19
So, it seems if you administer an anti-inflammatory drug by injection, it reduces inflammation.....just as dexamethasone ( a steroid) did.
Well, well, well....this really is leading science.
Monoclonal Antibodies are a mouthful for a normal person, but for Boris present special pronunciation problems - since he has even less idea what he’s talking about than usual.
Tocilizumab is part of the Recovery Trial, so gets priority treatment in Health Briefings/Press releases regardless of context as it represents another ‘stunning’ success for UK Research.
I feel sure that by now they would have overtaken John Lewis as mkt leaders in this sector.
Actually, the volume of late reported trades has died off in recent days.
I wonder if it’s the same 2-3m shares being traded each day, or if the placing shares are just being passed across, without the sp tanking?
https://www.thetimes.co.uk/article/gw-hits-high-notes-after-agreeing-7-2bn-takeover-by-jazz-tlc7vbqxw?shareToken=9bf40b974d921fdd01a44a5022eddbae
GW pharms - $7 to $220.
They have positive P2 results ( 40 patients) for their novel COPD treatment, which is a combined bronchodilator and anti- inflammatory.
No surprise, a couple of weeks ago, they announced they also have a P2 underway for it in Covid 19.
Worth considering that not every competitor is necessarily your ‘enemy’ if you’re both talking ‘treatments’.